Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Recent News

ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma
EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma
EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma
ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma
ASCO 2021: Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma
Final Evidence Report From ICER on Three Therapies Targeting BCMA for Myeloma
BCMA CAR T-Cell Therapy Granted Priority Review for Multiple Myeloma
Ixazomib, Lenalidomide, and Dexamethasone in Myeloma: Routine Clinical Practice Versus Clinical Trials
Selinexor-Based Triplet in Myeloma: Impact of Age and Frailty in BOSTON Trial
Combination of Novel Antimyeloma Prototype and Cyclopamine Under Study
Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma?
Peritransplant Orthostatic Hypotension and Multiple Myeloma
Frailty-Guided Treatment Strategy for Newly Diagnosed Patients With Myeloma
Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma
Whole-Genome Sequencing May Offer Insights to Multiple Myeloma Precursor Conditions
AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma
Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy
AACR 2021: Role of ROBO1 Receptor in Growth of Multiple Myeloma
Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial
Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma
Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy
AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?
Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?
ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma
Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma
Use of Generic Pomalidomide in India for Resistant Multiple Myeloma
Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial
FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma
FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma
Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma
Combination Regimens for Transplant-Ineligible Myeloma: From the Canadian Myeloma Research Group
Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma
Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma
Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma
Isolated Radiotherapy for Myeloma Lesions of the Cervical Spine: Case Report
Collaborative Initiative Offers Recommendations to Improve Diversity in Myeloma Trials
Long-Term Outcomes With Standard-of-Care Strategy in Multiple Myeloma
Melphalan Flufenamide Receives Accelerated Approval for Resistant Multiple Myeloma
Taking on Myeloma and Prostate Cancer: A Man Named Steele
TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?
Does a Patient’s Race Affect Access to IV Bisphosphonates in Multiple Myeloma?
Ixazomib Plus Standard Therapy for Myeloma: Outcomes in Routine Clinical Practice
Selinexor Triplet Under Study in Resistant Multiple Myeloma
Continued Trials for Iberdomide in Combination Therapy for Resistant Myeloma
Seeking the Right Dose of Immunoconjugate Combination in Resistant Myeloma
Corneal Changes With Antibody-Drug Conjugate in Myeloma: Mechanism Remains Unknown
Ixazomib Plus Standard Therapy in Transplant-Ineligible Patients With Myeloma
Cyclophosphamide Plus Weekly Carfilzomib and Dexamethasone in Resistant Myeloma
Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma
Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?
Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma
ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma
Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.